Christopher Cabell's most recent trade in Inhibikase Therapeutics Inc was a trade of 1,100,705 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Feb. 21, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Inhibikase Therapeutics Inc | Christopher Cabell | President & Head of R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2025 | 1,100,705 | 1,100,705 | - | - | Stock Option (Right to Buy) | |
| Inhibikase Therapeutics Inc | Christopher Cabell | President & Head of R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2025 | 1,100,705 | 1,100,705 | - | - | Stock Option (Right to Buy) | |
| Zura Bio Ltd - Ordinary Sh... | Christopher Cabell | CMO & Head of R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2023 | 162,060 | 162,060 | - | 0 | Class A Ordinary Shares | |
| Pulmatrix Inc | Christopher Cabell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jan 2023 | 1,700 | 1,700 | - | - | Stock Option (Right to Buy) | |
| Pulmatrix Inc | Christopher Cabell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jan 2022 | 22,100 | 22,100 | - | - | Stock Option (Right to Buy) | |
| Pulmatrix Inc | Christopher Cabell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jan 2021 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) |